Ewing sarcoma (Cancer)
Information
- Disease name
- Ewing sarcoma
- Disease ID
- DOID:3369
- Description
- "A connective tissue cancer that has_material_basis_in neural crest cells derives_from undeveloped, undifferentiated neuroectoderm." [url:http\://en.wikipedia.org/wiki/Primitive_neuroectodermal_tumor, url:http\://www.cancer.gov/dictionary?cdrid=383924]
Disease area statistics
Chromosome band
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01858168 | Active, not recruiting | Phase 1 | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma | July 2013 | December 2024 |
| NCT03478462 | Active, not recruiting | Phase 1 | Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | April 30, 2019 | December 2024 |
| NCT03220035 | Active, not recruiting | Phase 2 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | November 8, 2017 | September 22, 2024 |
| NCT02945800 | Active, not recruiting | Phase 2 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | October 25, 2016 | December 2024 |
| NCT00638898 | Active, not recruiting | Phase 1 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | February 26, 2007 | December 30, 2024 |
| NCT02076906 | Active, not recruiting | Phase 1 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | April 2014 | November 24, 2024 |
| NCT06451302 | Active, not recruiting | N/A | Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study | April 17, 2024 | December 31, 2027 |
| NCT02867592 | Active, not recruiting | Phase 2 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | May 18, 2017 | September 21, 2024 |
| NCT04483778 | Active, not recruiting | Phase 1 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | July 13, 2020 | December 2040 |
| NCT04067115 | Active, not recruiting | Phase 1/Phase 2 | SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients | January 5, 2021 | June 30, 2024 |
| NCT05302921 | Active, not recruiting | Phase 2 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | February 18, 2022 | July 1, 2025 |
| NCT03709680 | Active, not recruiting | Phase 1/Phase 2 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | May 24, 2019 | February 25, 2025 |
| NCT03600649 | Active, not recruiting | Phase 1 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | June 4, 2018 | December 2025 |
| NCT00026780 | Completed | Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | September 24, 2001 | October 7, 2020 | |
| NCT00674193 | Completed | Evaluating Dactinomycin and Vincristine in Young Patients With Cancer | February 2008 | ||
| NCT00743496 | Completed | Phase 1 | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma | October 8, 2008 | April 18, 2014 |
| NCT00931931 | Completed | Phase 1 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | March 2010 | March 19, 2018 |
| NCT01286987 | Completed | Phase 1 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | January 3, 2011 | January 30, 2017 |
| NCT01625351 | Completed | Phase 1 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | August 20, 2012 | February 10, 2020 |
| NCT02044120 | Completed | Phase 1 | ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma | May 2014 | January 2021 |
| NCT02100891 | Completed | Phase 2 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | March 20, 2013 | July 15, 2020 |
| NCT02520128 | Completed | N/A | A Study of IMRT in Primary Bone and Soft Tissue Sarcoma | March 2016 | June 30, 2020 |
| NCT02982941 | Completed | Phase 1 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | December 2016 | May 22, 2019 |
| NCT03190174 | Completed | Phase 1/Phase 2 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | August 24, 2017 | December 2, 2021 |
| NCT03245450 | Completed | Phase 1/Phase 2 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | March 5, 2018 | May 17, 2021 |
| NCT03441360 | Completed | Phase 2 | Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) | April 17, 2018 | January 21, 2022 |
| NCT04129151 | Completed | Phase 2 | Palbociclib + Ganitumab In Ewing Sarcoma | December 5, 2019 | December 15, 2022 |
| NCT04956198 | Completed | Drug Sensitivity and Mutation Profiling | November 17, 2020 | December 31, 2022 | |
| NCT05093322 | Completed | Phase 1/Phase 2 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | November 30, 2021 | April 25, 2023 |
| NCT05266196 | Enrolling by invitation | Phase 1/Phase 2 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | January 15, 2022 | December 2025 |
| NCT03029481 | No longer available | Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma | |||
| NCT06465199 | Not yet recruiting | Phase 1/Phase 2 | Difluoromethylornithine (DFMO) and AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas | July 2024 | July 2034 |
| NCT06395103 | Not yet recruiting | Phase 1/Phase 2 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | June 4, 2024 | March 31, 2029 |
| NCT03373097 | Recruiting | Phase 1/Phase 2 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | January 5, 2018 | December 2027 |
| NCT06340204 | Recruiting | Phase 1 | Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma | March 25, 2024 | December 25, 2026 |
| NCT05734066 | Recruiting | Phase 1/Phase 2 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | May 23, 2023 | June 2027 |
| NCT06156410 | Recruiting | Phase 1 | Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma | October 24, 2023 | November 2028 |
| NCT06243588 | Recruiting | Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma | January 25, 2024 | July 31, 2024 | |
| NCT03359005 | Recruiting | Phase 2 | Irinotecan and Temozolomide for Ewing Sarcoma | February 7, 2018 | February 28, 2025 |
| NCT04337177 | Recruiting | Phase 1 | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | October 25, 2021 | June 2024 |
| NCT04735289 | Recruiting | Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma | March 10, 2021 | December 31, 2024 | |
| NCT04758000 | Recruiting | Phase 2 | Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse | March 1, 2021 | July 2027 |
| NCT04791228 | Recruiting | Phase 2 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | November 10, 2022 | December 1, 2025 |
| NCT04897321 | Recruiting | Phase 1 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | July 6, 2022 | March 1, 2027 |
| NCT00840047 | Recruiting | Phase 2 | Methionine PET/CT Studies In Patients With Cancer | July 20, 2009 | July 27, 2027 |
| NCT04995003 | Recruiting | Phase 1 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | December 7, 2021 | December 31, 2040 |
| NCT05062707 | Recruiting | Early Ageing During Therapy in AYA Cancer Patients | February 10, 2022 | July 2025 | |
| NCT05182164 | Recruiting | Phase 2 | Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas | April 25, 2022 | October 31, 2025 |
| NCT05275426 | Recruiting | Phase 2 | A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor | March 2, 2022 | March 2, 2025 |
| NCT00898755 | Recruiting | Collecting and Storing Tissue From Young Patients With Cancer | March 5, 2007 | ||
| NCT05328258 | Recruiting | Phase 3 | Use of GnRHa During Chemotherapy for Fertility Protection | March 31, 2023 | January 31, 2032 |
| NCT05605522 | Recruiting | Phase 1 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | February 7, 2023 | September 2025 |
| NCT06094101 | Recruiting | Phase 1/Phase 2 | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) | September 19, 2023 | September 2027 |
| NCT05779670 | Recruiting | Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery | January 1, 2023 | December 31, 2025 | |
| NCT05918640 | Recruiting | Phase 1/Phase 2 | Lurbinectedin in FET-Fused Tumors | July 27, 2023 | July 30, 2028 |
| NCT05968768 | Recruiting | Phase 2 | To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) | October 24, 2023 | July 31, 2028 |
| NCT06029218 | Recruiting | N/A | Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy | September 13, 2023 | October 1, 2031 |
| NCT02508038 | Recruiting | Phase 1 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | February 12, 2016 | December 2025 |
| NCT06068075 | Recruiting | N/A | Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD | May 8, 2018 | January 1, 2026 |
| NCT03618381 | Recruiting | Phase 1 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | June 18, 2019 | June 2040 |
| NCT03715933 | Recruiting | Phase 1 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | October 10, 2018 | July 2026 |
| NCT04055220 | Recruiting | N/A | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | March 3, 2020 | October 1, 2026 |
| NCT04308330 | Recruiting | Phase 1 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | March 17, 2017 | December 31, 2024 |
| NCT03842865 | Temporarily not available | Expanded Access of Vigil in Solid Tumors | |||
| NCT03495921 | Terminated | Phase 3 | A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide | August 21, 2018 | January 20, 2022 |
| NCT03604783 | Terminated | Phase 1 | Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | December 26, 2018 | January 10, 2024 |
| NCT02624388 | Terminated | Phase 2 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) | August 2016 | September 2021 |
| NCT02581384 | Terminated | Phase 1/Phase 2 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | January 2017 | August 2020 |
| NCT01610570 | Terminated | Phase 1/Phase 2 | Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | May 10, 2012 | May 21, 2014 |
| NCT03458728 | Terminated | Phase 1/Phase 2 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | April 30, 2018 | February 1, 2023 |
| NCT04730349 | Terminated | Phase 1/Phase 2 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer | June 3, 2021 | June 22, 2022 |
| NCT02536183 | Terminated | Phase 1 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | October 2016 | October 2022 |
| NCT01882231 | Terminated | N/A | Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma | March 2013 | April 25, 2016 |
| NCT02409576 | Unknown status | Phase 1/Phase 2 | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas | February 2015 | September 2020 |
| NCT01780779 | Unknown status | Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults | June 2009 | June 2014 | |
| NCT02856048 | Unknown status | Phase 2/Phase 3 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer | November 23, 2016 | February 2021 |
| NCT01807468 | Unknown status | Phase 2 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | May 2013 | June 2019 |
| NCT02013336 | Unknown status | Phase 1 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | December 2013 | December 2023 |
| NCT03356782 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas | December 1, 2017 | December 31, 2023 |
| NCT04433221 | Unknown status | Phase 1/Phase 2 | Combination Immunotherapy Targeting Sarcomas | July 1, 2020 | December 31, 2023 |
| NCT01969942 | Withdrawn | Phase 1 | A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma | April 2013 | October 2016 |
| NCT03880123 | Withdrawn | Phase 1 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | November 2020 | November 24, 2020 |
| NCT01492569 | Withdrawn | N/A | Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting | May 2012 |
- Disase is a (Disease Ontology)
- DOID:201
- Cross Reference ID (Disease Ontology)
- GARD:6390
- Cross Reference ID (Disease Ontology)
- ICDO:9364/3
- Cross Reference ID (Disease Ontology)
- MESH:C563168
- Cross Reference ID (Disease Ontology)
- MESH:D012512
- Cross Reference ID (Disease Ontology)
- MESH:D018241
- Cross Reference ID (Disease Ontology)
- MIM:612219
- Cross Reference ID (Disease Ontology)
- NCI:C27901
- Cross Reference ID (Disease Ontology)
- NCI:C27903
- Cross Reference ID (Disease Ontology)
- NCI:C4817
- Cross Reference ID (Disease Ontology)
- NCI:C7542
- Cross Reference ID (Disease Ontology)
- NCI:C7806
- Cross Reference ID (Disease Ontology)
- NCI:C9341
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:134210007
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:73676002
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:76909002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0553580
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0684337
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0796547
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0863029
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0877849
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1334408
- Exact Synonym (Disease Ontology)
- Ewing's family localized tumor
- Exact Synonym (Disease Ontology)
- Ewing's sarcoma/peripheral primitive neuroectodermal tumor
- Exact Synonym (Disease Ontology)
- Ewing's tumor
- Exact Synonym (Disease Ontology)
- Ewings sarcoma
- Exact Synonym (Disease Ontology)
- Ewings sarcoma-primitive neuroectodermal tumor
- Exact Synonym (Disease Ontology)
- localized Ewing sarcoma
- Exact Synonym (Disease Ontology)
- localized Ewing's sarcoma
- Exact Synonym (Disease Ontology)
- localized Ewing's sarcoma/peripheral primitive neuroectodermal tumor
- Exact Synonym (Disease Ontology)
- localized Ewing's tumor
- Exact Synonym (Disease Ontology)
- localized peripheral primitive neuroectodermal tumor
- Exact Synonym (Disease Ontology)
- peripheral primitive neuroectodermal tumor
- Exact Synonym (Disease Ontology)
- PNET of Thoracopulmonary Region
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012254
- OrphaNumber from OrphaNet (Orphanet)
- 319